Why the study?
RBBB is considered a benign finding, but some studies have suggested increased cardiovascular morbidity and mortality, leaving the risk attributable to incidental RBBB in patients without CVD unclear.
Does incidental right bundle-branch block predict mortality in patients without known cardiovascular disease?
Does incidental right bundle-branch block predict mortality in patients without known cardiovascular disease?
In patients without known cardiovascular disease, incidental right bundle-branch block is associated with increased all-cause and cardiovascular mortality, suggesting it may be a marker of early subclinical disease.
Incidental RBBB should not yet change management in patients without known CVD; leaves open its value as an early marker needing prospective validation.
Background Right bundle‐branch block (RBBB) occurs in 0.2% to 1.3% of people and is considered a benign finding. However, some studies have suggested increased risk of cardiovascular morbidity and mortality. We sought to evaluate risk attributable to incidental RBBB in patients without prior diagnosis of cardiovascular disease (CVD). Methods and Results We reviewed the Mayo Clinic Integrated Stress Center database for exercise stress tests performed from 1993 to 2010. Patients with no known CVD—defined as absence of coronary disease, structural heart disease, heart failure, or cerebrovascular disease—were selected. Only Minnesota residents were included, all of whom had full mortality and outcomes data. There were 22 806 patients without CVD identified; 220 of whom (0.96%) had RBBB, followed for 6 to 23 years (mean 12.4±5.1). There were 8256 women (36.2%), mean age was 52±11 years; and 1837 deaths (8.05%), including 645 cardiovascular‐related deaths (2.83%), occurred over follow‐up. RBBB was predictive of all‐cause (hazard ratio [HR], 1.5; 95% CI, 1.1–2.0; P =0.0058) and cardiovascular‐related mortality (HR,1.7; 95% CI, 1.1–2.8; P =0.0178) after adjusting for age, sex, diabetes mellitus, hypertension, obesity, current and past history of smoking, and use of a heart rate‐lowering drug. Patients with RBBB exhibited more hypertension (34.1% versus 23.7%, P <0.0003), decreased functional aerobic capacity (82±25% versus 90±24%; P <0.0001), slower heart rate recovery (13.5±11.5 versus 17.1±9.4 bpm; P <0.0001), and more dyspnea (28.2% versus 22.4%; P <0.0399) on exercise testing. Conclusions Patients with RBBB without CVD have increased risk of all‐cause mortality, cardiovascular‐related mortality, and lower exercise tolerance. These data suggest RBBB may be a marker of early CVD and merit further prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Gaba et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: